Purchase Order 75N90023P00534
Award Date 6/23/23
Potential Completion Date 7/22/23
Potential Value $99K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Waltham, MA 02453, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- <p>The NIH Clinical Center awarded a purchase order to Olink Proteomics Inc. for Olink reagents valued at $24,607.29, effective July 1, 2026, with completion by September 30, 2026. Performance occurs in Waltham, Massachusetts. The order is firm fixed price with no small business set-aside.</p>
- The National Institutes of Health (NIH) Clinical Center's Critical Care Medicine Department (CCMD) has awarded a firm-fixed-price purchase order contract valued at $44,646.78 to Olink Proteomics Inc., a foreign-owned for-profit biotechnology company based in Waltham, Massachusetts. The contract is for the procurement of Olink Signature Q100 system reagents, including Olink Target 96 Inflammation, Olink 96.96 IFC for Protein Expression, and Olink Target 96 Organ Damage reagents. These reagents...
- This federal contract award, valued at $10,558.00, was issued by the National Institutes of Health (NIH) Clinical Center to Olink Proteomics Inc., a foreign-owned, for-profit biotechnology company based in Waltham, Massachusetts. The contract is for a service agreement to provide the Olink Signature Q100 System, which is an advanced proteomics instrument used for protein biomarker discovery and analysis. The contract has a period of performance from August 5, 2025 to August 4, 2026 and is a firm...
- This federal contract award was made by the National Institutes of Health (NIH) Clinical Center to Olink Proteomics Inc., a foreign-owned, for-profit biotechnology company. The $10,558 firm-fixed-price purchase order is for the delivery of Olink's proteomics instruments, reagent kits, integrated fluidic circuits, analysis services, and biological products to support biomedical research missions spanning aging, cancer, neurodegenerative diseases, diabetes, infectious diseases, and more. Olink...
- This firm fixed-price purchase order was awarded by the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute to Olink Proteomics AB, a foreign-owned for-profit organization, to provide Olink Biomarker Analysis Services. The $249,250.00 contract has a performance period through May 16, 2024 and does not have a set-aside designation. Olink Proteomics specializes in multiplex protein biomarker analysis platforms and has previously supported NIH, Food and Drug...
- Olink Proteomics AB was awarded a firm fixed price, indefinite delivery contract valued at up to $1,214,788 by the National Institutes of Health National Institute on Drug Abuse to provide biological and reagent materials as well as proteomics analysis services. Specializing in proprietary multiplex protein biomarker analysis technologies, Olink will support biomedical research efforts through delivery of Olink Explore and Target multiplex protein analysis kits, reagents, array chips, and...
- Olink Proteomics AB has been awarded a $10,078.96 purchase order by the National Institutes of Health's National Cancer Institute to provide biological and reagent materials for direct use. The firm fixed price contract runs from November 29, 2023 through December 31, 2023 and will be performed in Waltham, Massachusetts. No major subcontractors or set aside designations were indicated. The materials will support the National Cancer Institute's mission to lead the National Cancer Program and...
- This is a firm-fixed-price purchase order awarded by the National Institutes of Health (NIH) Clinical Center to Olink Proteomics Inc., a foreign-owned, for-profit biotechnology company. The $14,531.69 contract is for the provision of Olink's proprietary proteomics instruments, reagent kits, integrated fluidic circuits, and analytical services to support biomedical research missions across the NIH, including aging, cancer, neurodegenerative diseases, diabetes, and infectious diseases. Olink...
- This purchase order, valued at $77,330, was awarded by the National Institutes of Health's National Cancer Institute to Olink Proteomics Inc. to provide normalized expression data from multiplexed immunoassays using the Olink Explore 3072 platform. The services will support research conducted by the Pediatric Oncology Branch. As a sole source award under FAR Part 12, the contract calls for Olink to leverage its proprietary technology to deliver specialized proteomics analysis services to NIH/NCI...
- The Department of Health and Human Services, National Institutes of Health, National Cancer Institute awarded a $97,210 firm fixed price purchase order to Olink Proteomics Inc. to deliver one Olink Signature Q100 instrument and associated accessories in support of proteomics research at the Center for Cancer Research, Center for Immuno-Oncology. Per the original solicitation, the acquisition is for the instrument, accessories, delivery, installation if required, and after-sales...